Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Emcyt
2. Estracyt
3. Estramustin Phosphate
4. Estramustine
5. Estramustine Phosphate Sodium
6. Estramustinphosphate
7. Leo 275
8. Leo-275
9. Leo275
10. Nsc 89199
11. Nsc-89199
12. Nsc89199
13. Phosphate Sodium, Estramustine
14. Phosphate, Estramustin
1. 4891-15-0
2. Estracyt
3. Emcyt (free Acid)
4. Leo 299
5. Ls 299
6. Nsc-89199
7. Estramustine 17-(dihydrogen Phosphate)
8. Chembl1756
9. Muz9585y7b
10. Chebi:68643
11. Ls-299
12. (8r,9s,13s,14s,17s)-13-methyl-17-(phosphonooxy)-7,8,9,11,12,13,14,15,16,17-decahydro-6h-cyclopenta[a]phenanthren-3-yl Bis(2-chloroethyl)carbamate
13. Estradiol, 3-(bis(2-chloroethyl)carbamate) Dihydrogen Phosphate
14. Estra-1,3,5(10)-triene-3,17beta-diol 3-[bis(2-chloroethyl)carbamate] 17-(dihydrogen Phosphate)
15. Estradiol, 3-[bis(2-chloroethyl)carbamate] Dihydrogen Phosphate
16. (17beta)-17-(phosphonooxy)estra-1(10),2,4-trien-3-yl Bis(2-chloroethyl)carbamate
17. Nsc 89199
18. Unii-muz9585y7b
19. Ncgc00184995-01
20. Estra-1,3,5(10)-triene-3,17beta-diol 3-(bis(2-chloroethyl)carbamate) 17-(dihydrogen Phosphate)
21. Nsc89199
22. Einecs 225-512-3
23. Estramustine-phosphate
24. Brn 1898199
25. Dsstox_cid_28593
26. Dsstox_rid_82864
27. Dsstox_gsid_48667
28. Schembl234749
29. Dtxsid7048667
30. Zinc3938713
31. Tox21_113033
32. Bdbm50333645
33. Hy-13627a
34. Akos025401368
35. Ac-1305
36. Db14674
37. Estramustine Phosphate [who-dd]
38. Ncgc00484900-01
39. [(8r,9s,13s,14s,17s)-13-methyl-17-phosphonooxy-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] N,n-bis(2-chloroethyl)carbamate
40. Estra-1,3,5(10)-triene-3,17-diol (17beta)-, 3-(bis(2-chloroethyl)carbamate) 17-(dihydrogen Phosphate)
41. Cas-4891-15-0
42. Cs-0133861
43. Ab01273936-01
44. 891e150
45. Estramustine 17-(dihydrogen Phosphate) [mi]
46. Q27137070
47. Estra-1,3,5(10)-triene-3,17
48. A-diol 3-[bis(2-chloroethyl)carbamate] 17-(dihydrogen Phosphate)
49. Estra-1,3,5(10)-triene-3,17beta-diol3-[bis(2-chloroethyl)carbamate]17-(dihydrogenphosphate)
50. Estra-1,5(10)-triene-3,17-diol (17.beta.)-, 3-[bis(2-chloroethyl)carbamate] 17-(dihydrogen Phosphate)
Molecular Weight | 520.4 g/mol |
---|---|
Molecular Formula | C23H32Cl2NO6P |
XLogP3 | 2.9 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 8 |
Exact Mass | 519.1344301 g/mol |
Monoisotopic Mass | 519.1344301 g/mol |
Topological Polar Surface Area | 96.3 Ų |
Heavy Atom Count | 33 |
Formal Charge | 0 |
Complexity | 747 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 5 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Antineoplastic Agents, Hormonal
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)
Antineoplastic Agents, Alkylating
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026) (See all compounds classified as Antineoplastic Agents, Alkylating.)
ABOUT THIS PAGE
A Estramustine phosphate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Estramustine phosphate, including repackagers and relabelers. The FDA regulates Estramustine phosphate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Estramustine phosphate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Estramustine phosphate supplier is an individual or a company that provides Estramustine phosphate active pharmaceutical ingredient (API) or Estramustine phosphate finished formulations upon request. The Estramustine phosphate suppliers may include Estramustine phosphate API manufacturers, exporters, distributors and traders.
Estramustine phosphate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Estramustine phosphate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Estramustine phosphate GMP manufacturer or Estramustine phosphate GMP API supplier for your needs.
A Estramustine phosphate CoA (Certificate of Analysis) is a formal document that attests to Estramustine phosphate's compliance with Estramustine phosphate specifications and serves as a tool for batch-level quality control.
Estramustine phosphate CoA mostly includes findings from lab analyses of a specific batch. For each Estramustine phosphate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Estramustine phosphate may be tested according to a variety of international standards, such as European Pharmacopoeia (Estramustine phosphate EP), Estramustine phosphate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Estramustine phosphate USP).
LOOKING FOR A SUPPLIER?